The effect of sibutramine intake on resting and exercise physiological responses
- PMID: 18230966
- DOI: 10.1159/000114290
The effect of sibutramine intake on resting and exercise physiological responses
Abstract
Aim: To evaluate the effect of a short-term sibutramine intake on energy expenditure and on physiological responses during rest, submaximal exercise and maximal exercise in obese women.
Methods: Fifteen healthy obese female volunteers were randomly assigned to either a placebo (n = 6 - control) or sibutramine group (n = 9 - experimental) under double-blind conditions. Each subject was tested under resting conditions and then performed submaximal and maximal exercise tests. Subjects were retested under identical conditions following a 5-day administration of either sibutramine 10 mg x day(-1) or a placebo. All measurements (i.e. weight, body composition, resting energy expenditure, heart rate, respiratory exchange ratio, ventilation, oxygen consumption, carbon dioxide production, systolic blood pressure, diastolic blood pressure and blood lactate concentration) were analyzed using a 2-way ANOVA with repeated measures.
Results: Only heart rate during submaximal exercise was significantly different (higher) following short-term sibutramine administration when compared to placebo (p < 0.05).
Conclusions: These data suggest that a recommended daily dose of 10 mg sibutramine does not affect energy expenditure or other selected cardiopulmonary responses during rest, submaximal exercise or maximal exercise. It is, therefore, suggested that weight loss during sibutramine treatment in humans is achieved mostly via a decrease in energy intake rather than through an increase in energy expenditure and thermogenesis.
(c) 2008 S. Karger AG, Basel.
Similar articles
-
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):24-30. doi: 10.1016/j.numecd.2004.07.002. Nutr Metab Cardiovasc Dis. 2005. PMID: 15871847 Clinical Trial.
-
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S31-8; discussion S39. doi: 10.1038/sj.ejcn.1602172. Eur J Clin Nutr. 2005. PMID: 16052193 Clinical Trial.
-
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.Am Heart J. 2001 Sep;142(3):489-97. doi: 10.1067/mhj.2001.117510. Am Heart J. 2001. PMID: 11526363 Clinical Trial.
-
Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:35-40. doi: 10.1055/s-0029-1212035. Exp Clin Endocrinol Diabetes. 1998. PMID: 9792480 Review.
-
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:29-34. doi: 10.1055/s-0029-1212034. Exp Clin Endocrinol Diabetes. 1998. PMID: 9792479 Review.
Cited by
-
Interventions associated with brown adipose tissue activation and the impact on energy expenditure and weight loss: A systematic review.Front Endocrinol (Lausanne). 2022 Dec 9;13:1037458. doi: 10.3389/fendo.2022.1037458. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36568070 Free PMC article.
-
Brown and Beige Adipose Tissue: One or Different Targets for Treatment of Obesity and Obesity-Related Metabolic Disorders?Int J Mol Sci. 2024 Dec 11;25(24):13295. doi: 10.3390/ijms252413295. Int J Mol Sci. 2024. PMID: 39769065 Free PMC article. Review.